prnewswire.com
Negativewww.prnewswire.com ·
lillys omvoh mirikizumab mrkz is the first and only il 23p19 to demonstrate durable disease clearance in ulcerative colitis through four years 302760458
TAX_DISEASE_INFECTIONMEDIA_SOCIALPROTESTGENERAL_HEALTH
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThis is a clinical efficacy announcement for a specific drug (Omvoh) in a specific indication (ulcerative colitis). The commercial mechanism is weak: while positive data may support market share growth and pricing power for Eli Lilly in the IBD space, no revenue figures, pricing changes, supply constraints, or competitor impacts are mentioned. The impact is company-specific and limited to the IL-23p19 inhibitor class.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Eli Lilly's Omvoh (mirikizumab-mrkz) is the first IL-23p19 inhibitor to show durable disease clearance in UC over four years.
- In LUCENT-3 study, 63.5% of patients who achieved disease clearance at one year maintained it after four years.
- Omvoh is approved in 47 countries for UC and Crohn's disease in adults.